The KAT9/Elp3 antibody targets Elongator complex subunit 3 (Elp3), a multifunctional protein involved in transcriptional regulation and tRNA modification. Elp3. also known as KAT9 (lysine acetyltransferase 9), is a catalytic subunit of the evolutionarily conserved Elongator complex, which plays roles in transcriptional elongation, histone modification, and neurodevelopment. Structurally, Elp3 contains a radical S-adenosylmethionine (SAM) domain and a lysine acetyltransferase (KAT) domain, enabling its dual enzymatic activity in acetylating histone H3 (primarily at lysine 14) and participating in tRNA wobble uridine modifications.
Antibodies against Elp3 are widely used to study its role in epigenetic regulation, neuronal function, and diseases. Dysregulation of Elp3 has been linked to neurodevelopmental disorders, amyotrophic lateral sclerosis (ALS), and cancer. In research, Elp3 antibodies are employed in techniques like chromatin immunoprecipitation (ChIP), Western blotting (WB), and immunofluorescence (IF) to investigate its interaction with chromatin, subcellular localization, and expression levels. Notably, Elp3's acetyltransferase activity is crucial for acetylation of α-tubulin and other non-histone proteins, impacting cytoskeletal dynamics and cellular signaling. Studies using Elp3 antibodies have also clarified its involvement in stress responses, DNA damage repair, and metabolic pathways. Commercial Elp3 antibodies are typically validated for specificity in model organisms, including humans, mice, and Drosophila, facilitating cross-species mechanistic studies.